Dr. Reddy's Laboratories Ltd. (RDY)
| Market Cap | 8.49B |
| Revenue (ttm) | 2.58B |
| Net Income (ttm) | 234.85M |
| Shares Out | 165.96M |
| EPS (ttm) | 2.04 |
| PE Ratio | 25.02 |
| Forward PE | 19.57 |
| Dividend | $0.34 (0.67%) |
| Ex-Dividend Date | n/a |
| Volume | 231,728 |
| Open | 50.85 |
| Previous Close | 50.68 |
| Day's Range | 50.66 - 51.26 |
| 52-Week Range | 47.88 - 75.50 |
| Beta | 0.15 |
| Analysts | Buy |
| Price Target | 67.78 (+32.5%) |
| Earnings Date | May 13, 2022 |
About RDY
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics bu...
Financial Performance
In 2020, RDY's revenue was 189.72 billion, an increase of 8.66% compared to the previous year's 174.60 billion. Earnings were 17.24 billion, a decrease of -11.59%.
Financial numbers in millions INRFinancial StatementsAnalyst Forecast
According to 45 analysts, the average rating for RDY stock is "Buy." The 12-month stock price forecast is 67.78, which is an increase of 32.51% from the latest price.
News
New Strong Sell Stocks for May 12th
CHUY, RDY, and FBC have been added to the Zacks Rank #5 (Strong Sell) List on May 12, 2022.
11 Emerging Market Stocks That Analysts Love
Right now, it's easy to be down on the global stock market. While the U.S. market is off about 7% so far in 2022, emerging market stocks are about 10% lower than where they were to start the year.
Dr. Reddy's Laboratories Announces the Launch of Posaconazole Delayed-Release Tablets in the U.S. Market
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)-- #DRREDDY--Dr. Reddy's Laboratories announces the launch of Posaconazole Delayed-Release Tablets in the U.S. Market.
Dr. Reddy's Laboratories Announces the Launch of Methylprednisolone Sodium Succinate for Injection, USP in the U.S. M...
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)-- #DRREDDY--Dr. Reddy's Laboratories announces the launch of Methylprednisolone Sodium Succinate for Injection, USP in the U.S. Market.
Dr. Reddy's Laboratories and MediCane Health Announce the Launch of Medical Cannabis Products in Germany
AUGSBURG, Germany & VANCOUVER, British Columbia & HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories and MediCane Health announce the launch of medical cannabis products in Germany.
Dr. Reddy's Laboratories Announces the Launch of Its Authorized Generic Version of VASOSTRICT® (vasopressin injection...
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)-- #DrReddys--Dr. Reddy's Laboratories announces the launch of its authorized generic version of VASOSTRICT® Vials in the U.S. Market.
NYSE-Listed Pharma Co. Dr. Reddy's To Acquire German Medical Cannabis Firm Nimbus Health GmbH
Pharmaceutical company Dr. Reddy's Laboratories Ltd. RDY has entered into a definitive agreement to acquire Nimbus Health GmbH, a medical cannabis-focused licensed pharmaceutical wholesaler from Germany.
Dr. Reddy's Laboratories Enters Into Definitive Agreement to Acquire German Medical Cannabis Firm Nimbus Health GmbH
FRANKFURT, Germany & HYDERABAD, India--(BUSINESS WIRE)-- #DrReddys--Dr. Reddy's Laboratories enters into definitive agreement to acquire German medical cannabis firm Nimbus Health GmbH.
Dr. Reddy's Included in S&P Global's Sustainability Yearbook for the 2nd Year and Bloomberg Gender-Equality Index for...
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter referred to as “Dr. Reddy's”) announces two major back-to-back recogni...
Dr. Reddy's (RDY) Q3 Earnings, Sales Increase Year Over Year
Dr. Reddy's (RDY) earnings and revenues increase year over year in third-quarter fiscal 2022.
Reddy's To Launch Generic Version Of Merck's COVID-19 Drug At $0.50/Pill: Reuters
India-based Dr Reddy's Laboratories Ltd (NYSE: RDY) will launch its generic version of Merck Co & Inc's (NYSE: MRK) COVID-19 antiviral pill, reported Reuters. A company spokesperson said Reddy's would l...
3 Generic Drug Stocks to Watch Amid Stabilizing Pricing Pressure
The impact of COVID-19 on the Zacks Medical-Generic Drugs industry remains mixed. The stabilization in price in 2021 and new product launches may provide some respite for RDY, TEVA and AMPH.
Dr. Reddy's and Prestige BioPharma announce partnership to commercialize biosimilar for cancer treatment in select co...
HYDERABAD, India--(BUSINESS WIRE)-- #DRREDDY--Prestige BioPharma and Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter referred to as “Dr. Reddy's”) today ...
Prestige BioPharma and Dr. Reddy's Announce Partnership to Commercialize Trastuzumab Biosimilar in Select Countries i...
SINGAPORE & HYDERABAD, India--(BUSINESS WIRE)-- #DRREDDY--Prestige BioPharma and Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter referred to as “Dr. Redd...
Dr. Reddy's Laboratories Announces the Launch of Venlafaxine ER Tablets in the U.S. Market
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy...
Dr. Reddy's Laboratories Announces the Launch of Valsartan Tablets, USP in the U.S. Market
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy...
New Strong Sell Stocks for November 22nd
RDY, FRO, WWW, PGR, and LGIH have been added to the Zacks Rank #5 (Strong Sell) List on November 22, 2021.
Dr. Reddy's Ready To Make COVID-19 Antiviral From Pfizer - Reuters
Dr. Reddy's Laboratories Ltd (NYSE: RDY) said it was open to making Pfizer Inc's (NYSE: PFE) COVID-19 antiviral pill, Reuters reported. The new drugs can be used to treat patients once they contract cor...
New Strong Sell Stocks for November 4th
ALX, RDY, HSC, LAWS, and ANDE have been added to the Zacks Rank #5 (Strong Sell) List on November 4, 2021.
Dr. Reddy's (RDY) Q2 Earnings, Sales Increase Year Over Year
Dr. Reddy's (RDY) earnings and revenues increase year over year in second-quarter fiscal 2022.
Dr. Reddy's Laboratories Announces the Launch of Ephedrine Sulfate Injection USP, 50 mg/mL, Single-Dose Vial in the U...
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy...
Dr. Reddy's Laboratories Announces Approval for Lenalidomide Capsules from the U.S. Food and Drug Administration (USFDA)
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy...
Dr. Reddy's Laboratories Announces the Launch of Carmustine for Injection, USP in the U.S. Market
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy...
AiPharma Signs Binding Agreement To Sell To Aditxt Inc (Nasdaq: ADTX). AiPharma Is The Rights Holder Of Antiviral Tab...
DUBAI, United Arab Emirates, Oct. 5, 2021 /PRNewswire/ -- AiPharma Global Holdings LLC ("AiPharma") a company focused on discovering, developing and commercializing antiviral therapies across a broad sp...
Citius (CTXR) Acquires Dr. Reddy's License for NHL Therapy
Citius Pharmaceuticals (CTXR) acquires Dr. Reddy's exclusive license rights for E7777 to treat a rare form of NHL and other cancer indications.